Showing 3461-3470 of 4062 results for "".
- Haag-Streit Realigns its Organization to Focus on Solutions in Eye Carehttps://modernod.com/news/haag-streit-realigns-its-organization-to-focus-on-solutions-in-eye-care/2480595/As of January 1, 2022, Haag-Streit Group has realigned its organization to focus on eye
- The Vision Council Concludes Virtual Annual Business Meetinghttps://modernod.com/news/the-vision-council-concludes-virtual-annual-business-meeting/2480592/The Vision Council hosted its annual Business Meeting in a virtual format January 24. Presented under the banner of “It’s All Connected,” the meeting included a welcome address from Karen Roberts, The Vision Council’s Chair, followed by remarks from Ashley Mil
- Yehia Hashad, MD, to Join Bausch + Lomb as Executive Vice President of Research & Development and CMOhttps://modernod.com/news/yehia-hashad-md-will-join-bausch-lomb-as-executive-vice-president-of-research-development-and-cmo/2480581/Bausch Health Companies has announced that Yehia Hashad, MD, will join Bausch + Lomb as executive vice president of Research & Development and Chief Medical Officer (CMO), effective January 31, 2022. Dr. Hashad will join Bausch + Lomb from Allergan/AbbVie, where for the past 11
- Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officerhttps://modernod.com/news/foundation-fighting-blindness-promotes-jason-menzo-to-president-and-chief-operating-officer/2480580/The Foundation Fighting Blindness announced the promotion of Jason Menzo to president and chief operating officer, effective immediately. Since joining the Foundation in 2018, Mr. Menzo has had a profound positive impact on redefining the non-profit’s operations, includi
- Kubota Vision Initiates PBOS Prospective Study in Patientshttps://modernod.com/news/kubota-vision-initiates-pbos-prospective-study-in-patients/2480577/Kubota Vision announced that on January 17, 2022, the first patient has enrolled and completed the first visit in a prospective study in Japan using the company's Patient Based Ophthalmology Suite (PBOS), in-home optical coherence tomography (OCT) device. The study is being led by S
- NIH Researchers Develop First Stem Cell Model of Albinism to Study Related Eye Conditionshttps://modernod.com/news/nih-researchers-develop-first-stem-cell-model-of-albinism-to-study-related-eye-conditions/2480560/Researchers at the National Eye Institute (NEI) have developed the first patient-derived stem cell model for studying eye conditions related to oculocutaneous albinism (OCA). The model’s development is described in the January issue of the journal Stem Cell
- Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Election of Thomas W. Burns as New Chairmanhttps://modernod.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/Glaukos announced that William J. Link, PhD, will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos&rs
- Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officerhttps://modernod.com/news/aerie-pharmaceuticals-appoints-raj-kannan-as-chief-executive-officer/2480519/Aerie Pharmaceuticals announced that Raj Kannan will join the company as Chief Executive Officer and a director, effective December 20, 2021. “On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search pro
- Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Diseasehttps://modernod.com/news/kiora-reports-kio-101-is-safe-and-tolerable-for-dry-eye-disease/2480512/Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safe
- Omeros to Sell Omidria Franchise to Rayner in a Deal Worth More Than $1 Billionhttps://modernod.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/Omeros announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group. The transaction, which is expected to close on or before December 31, 2021, includes an upfront payment of $125 million with an additional $200 million in